Literature DB >> 35481878

Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma.

Laura A Evans1, Emilie A Anderson1, Erik Jessen2, Bharat Nandakumar1, Ezgi Atilgan1, Dragan Jevremovic3, Taro Hitosugi4, Rafael Fonseca5, Shaji K Kumar1, Wilson I Gonsalves1.   

Abstract

Altered energy metabolism and changes in glycolytic and oxidative phosphorylation pathways are hallmarks of all cancer cells. The expression of select genes associated with the production of various enzymes and proteins involved in glycolysis and oxidative phosphorylation were assessed in the clonal plasma cells derived from patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Multiple Myeloma Research Foundation (MMRF) CoMMpass data set. A scoring system consisting of assigning a point for every gene where their fragments per kilobase of transcript per million (FPKM) was above the median yielded a minimum of 0 and a maximum of 12 for the set of genes in the glycolytic and oxidative phosphorylation pathways to create a total energy metabolism molecular signature (EMMS) score. This EMMS score was independently associated with worse progression free survival (PFS) and overall survival (OS) outcomes of patients with NDMM. A higher EMMS score was more likely to be present in clonal plasma cells derived from Multiple myeloma (MM) patients than those from patients with monoclonal gammopathy of undetermined significance (MGUS). This was functionally confirmed by the clonal plasma cells from MM patients having a higher rate of mitochondrial and glycolysis-derived ATP formation than clonal plasma cells from MGUS patients. Thus, this study provides evidence for the effect of energy metabolism within clonal plasma cells on pathogenesis and outcomes of patients with MM. Exploiting the energy-producing metabolic pathways within clonal plasma cells for diagnostic and therapeutic purposes in MM should be explored in the future.
© 2022 Wiley Periodicals LLC.

Entities:  

Mesh:

Year:  2022        PMID: 35481878      PMCID: PMC9197880          DOI: 10.1002/ajh.26577

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   13.265


  21 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  A gene expression signature for high-risk multiple myeloma.

Authors:  R Kuiper; A Broyl; Y de Knegt; M H van Vliet; E H van Beers; B van der Holt; L el Jarari; G Mulligan; W Gregory; G Morgan; H Goldschmidt; H M Lokhorst; M van Duin; P Sonneveld
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

3.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.

Authors:  M C Trendle; T Leong; R A Kyle; J A Katzmann; M M Oken; N E Kay; B G Van Ness; P R Greipp
Journal:  Am J Hematol       Date:  1999-08       Impact factor: 10.047

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.

Authors:  Wilson I Gonsalves; Vijay Ramakrishnan; Taro Hitosugi; Toshi Ghosh; Dragan Jevremovic; Tumpa Dutta; Dhananjay Sakrikar; Xuan-Mai Petterson; Linda Wellik; Shaji K Kumar; K Sreekumaran Nair
Journal:  JCI Insight       Date:  2018-01-11

Review 7.  Links between metabolism and cancer.

Authors:  Chi V Dang
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

Review 8.  Hallmarks of Cancer: New Dimensions.

Authors:  Douglas Hanahan
Journal:  Cancer Discov       Date:  2022-01       Impact factor: 39.397

Review 9.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

10.  Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.

Authors:  Richa Bajpai; Aditi Sharma; Abhinav Achreja; Claudia L Edgar; Changyong Wei; Arusha A Siddiqa; Vikas A Gupta; Shannon M Matulis; Samuel K McBrayer; Anjali Mittal; Manali Rupji; Benjamin G Barwick; Sagar Lonial; Ajay K Nooka; Lawrence H Boise; Deepak Nagrath; Mala Shanmugam
Journal:  Nat Commun       Date:  2020-03-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.